EDIT
Editas Medicine, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$2.67Close
$261.3MMarket cap
$1.66 – $3.7552-week range
Nov 9, 2026Next report
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 49 · weaker than 51% of stocks over 12 months
- Far from its high 29% below its 52-week high
- Results soon Nov 9, 2026, in 8 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
29%
1wk
up 11.2%
price change
1mo
up 3.9%
price change
12-month return
down 11%
market up 11% ·
its own down 23%
F-score
—
— Not assessed
Altman Z
-13.09
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
9.6×
price / book
Earnings yield
down 95.1%
EBIT / enterprise value
Cheaper than
6%
of the market · expensive
Revenue growth
up 25%
year on year
EPS growth
—
latest quarter
Sales growth
up 232%
latest quarter · +272 pts
ROE
down 198%
return on equity
Free cash margin
down 409%
-$165.8M FCF
D/E
1.96
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Piotroski tests
Repair signals
- Revenue reaccelerating (-59% then +25%)
Trade setup
ATR%
7.9%
$0.21 a day · 2×ATR $2.25
RS
49 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
1.1×
vs 50-day average
Up/down volume
0.88
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 18.3% over the year, from 83m to 98m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+5% vs market2 sessions after results
Financials
- Net -395%
- Free cash -409%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M |
| Operating income | -$134.8M | -$193.1M | -$225.9M | -$169.2M | -$251.2M | -$160.0M |
| Net income | -$116.0M | -$192.5M | -$220.4M | -$153.2M | -$237.1M | -$160.1M |
| Net margin | -128% | -754% | -1118% | -196% | -734% | -395% |
| Earnings per share | -$1.98 | -$2.85 | -$3.21 | -$2.02 | -$2.88 | -$1.80 |
| Free cash flow | -$187.0M | -$171.8M | -$181.5M | -$136.9M | -$219.1M | -$165.8M |
| Free cash margin | -206% | -672% | -921% | -175% | -678% | -409% |
| Cash | $139.7M | $203.5M | $141.5M | $123.7M | $131.5M | $146.6M |
| Long-term debt | — | — | — | $0 | $52.4M | $53.6M |
| Shareholders' equity | $393.6M | $553.6M | $360.7M | $349.1M | $134.3M | $27.3M |
| Shares outstanding | 62.56m | 68.44m | 68.85m | 81.77m | 82.73m | 97.87m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Mar 9, 2026 | Annual ↗ | Dec 31, 2025 | 68d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 5, 2025 | Annual ↗ | Dec 31, 2024 | 64d |
| Nov 4, 2024 | Quarterly ↗ | Sep 30, 2024 | 35d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 3, 2023 | Quarterly ↗ | Sep 30, 2023 | 34d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 8, 2026 | Regulation FD · Other events ↗ |
| Aug 5, 2026 | Results · Director or officer change ↗ |
| Jun 18, 2026 | Shareholder vote ↗ |
| May 26, 2026 | Material agreement · Other events ↗ |
| May 26, 2026 | Other events ↗ |
| May 26, 2026 | Regulation FD · Other events ↗ |
| May 14, 2026 | Regulation FD · Other events ↗ |
| May 5, 2026 | Results ↗ |
| Apr 7, 2026 | Auditor change ↗ |
| Mar 27, 2026 | Regulation FD · Other events ↗ |
| Mar 9, 2026 | Results ↗ |
| Nov 10, 2025 | Results ↗ |